Aliases & Classifications for Sensorineural Hearing Loss

MalaCards integrated aliases for Sensorineural Hearing Loss:

Name: Sensorineural Hearing Loss 12 76 29 6 15 73
Sensory Hearing Loss 12 55 73
Hearing Loss, High-Frequency 44 73
Hearing Loss, Central 44 73
Perceptive Hearing Loss or Deafness 12
High Frequency Hearing Loss 12
High-Frequency Hearing Loss 12
Hearing Loss High-Frequency 55
Hearing Loss, Sensorineural 44
Hearing Loss Sensorineural 55
High Frequency Deafness 12
Perceptive Hearing Loss 12
Sensorineural Deafness 12
Deafness Sensorineural 55
Central Hearing Loss 12
Perceptive Deafness 12

Classifications:



Summaries for Sensorineural Hearing Loss

MalaCards based summary : Sensorineural Hearing Loss, also known as sensory hearing loss, is related to deafness, x-linked 2 and deafness, autosomal dominant 22, and has symptoms including tinnitus An important gene associated with Sensorineural Hearing Loss is MT-TL1 (Mitochondrially Encoded TRNA Leucine 1 (UUA/G)), and among its related pathways/superpathways is Gap junction trafficking. The drugs Cisplatin and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and brain, and related phenotypes are hearing/vestibular/ear and behavior/neurological

Wikipedia : 76 Sensorineural hearing loss (SNHL) is a type of hearing loss, or deafness, in which the root cause lies... more...

Related Diseases for Sensorineural Hearing Loss

Diseases related to Sensorineural Hearing Loss via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 653)
# Related Disease Score Top Affiliating Genes
1 deafness, x-linked 2 34.1 GJB2 GJB6
2 deafness, autosomal dominant 22 33.3 COCH MYH9 MYO6 MYO7A
3 deafness, autosomal dominant 36 33.3 GJB2 SLC26A4 TMC1
4 deafness, autosomal recessive 9 33.2 GJB2 OTOF
5 auditory neuropathy, autosomal dominant, 1 33.1 GJB2 OTOF
6 deafness, autosomal dominant 48 33.1 MYH9 MYO6 MYO7A
7 deafness, autosomal recessive 37 33.0 MYH9 MYO6 MYO7A
8 deafness, autosomal recessive 23 33.0 GJB2 GJB6 MYO7A SLC26A4
9 deafness, autosomal recessive 6 33.0 GJB2 MYO7A USH2A
10 deafness, autosomal recessive 2 32.9 GJB2 MYO6 MYO7A OTOF
11 deafness, autosomal recessive 7 32.9 GJB2 TMC1
12 deafness, autosomal recessive 28 32.8 GJB2 GJB3
13 deafness, autosomal recessive 3 32.6 GJB2 MYO7A
14 usher syndrome 32.6 CEP78 GJB2 MYO7A USH2A
15 deafness, autosomal recessive 1a 32.6 GJB2 GJB3 GJB6 OTOF
16 knuckle pads, leukonychia, and sensorineural deafness 32.6 GJB2 GJB6
17 deafness, autosomal dominant 11 32.4 MYO6 MYO7A
18 deafness, autosomal dominant 2a 32.4 COCH GJB2 GJB6 KCNQ4 WFS1
19 deafness, autosomal dominant 6 32.3 COCH GJB2 MYO7A OTOF SLC26A4 WFS1
20 usher syndrome, type iiia 32.3 CEP78 MYO7A USH2A
21 congenital cytomegalovirus 32.1 GJB2 GJB6
22 mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratoderma 32.0 GJB2 GJB3 MITF
23 deafness, autosomal recessive 16 31.9 COCH GJB2 GJB6 MYO7A OTOF SLC26A4
24 deafness, autosomal dominant 24 31.9 GJB2 GJB6
25 auditory neuropathy spectrum disorder 31.8 MYO7A OTOF
26 deafness, autosomal recessive 59 31.8 GJB2 OTOF
27 deafness, autosomal recessive 26 31.8 GJB2 OTOF SLC26A4
28 deafness, autosomal dominant 13 31.7 COCH GJB2 MYO7A OTOF SLC26A4 USH2A
29 deafness, autosomal recessive 85 31.7 MYO7A OTOF SLC26A4
30 deafness, autosomal recessive 83 31.6 MYO7A OTOF SLC26A4
31 autosomal recessive nonsyndromic deafness 31.6 GJB2 OTOF SLC26A4 TMC1
32 deafness, autosomal recessive 4, with enlarged vestibular aqueduct 31.6 COCH GJB2 GJB3 GJB6 MYO7A OTOF
33 deafness, autosomal dominant 17 31.5 MYH9 MYO6 MYO7A
34 hypotrichosis-deafness syndrome 31.4 GJB2 GJB3
35 deafness, autosomal recessive 93 31.4 GJB2 GJB3
36 autosomal dominant non-syndromic sensorineural deafness type dfna 31.1 COCH GJB2 GJB3 GJB6 KCNQ4 MYH9
37 dfnb1 31.1 GJB2 GJB6 MYO7A OTOF
38 autosomal recessive nonsyndromic deafness 3 31.0 GJB2 MYH9 MYO6 MYO7A OTOF SLC26A4
39 deafness, autosomal recessive 30 31.0 GJB2 MYH9 MYO6 MYO7A SLC26A4 TMC1
40 knuckle pads 31.0 GJB2 GJB3 GJB6
41 kid syndrome 30.7 GJB2 GJB3 GJB6
42 clouston syndrome 30.6 GJB2 GJB3 GJB6
43 non-syndromic genetic deafness 29.7 COCH GJB2 KCNQ4 MYH9 MYO6 OTOF
44 autosomal recessive non-syndromic sensorineural deafness type dfnb 29.6 GJB2 GJB3 GJB6 MYH9 MYO6 MYO7A
45 autosomal dominant nonsyndromic deafness 29.1 COCH GJB2 GJB3 KCNQ4 MYH9 MYO6
46 auditory system disease 28.7 ATP6V1B1 COCH GJB2 GJB3 GJB6 KCNQ4
47 nonsyndromic deafness 27.2 COCH GJB2 GJB3 GJB6 KCNQ4 MITF
48 split-hand/foot malformation 1 with sensorineural hearing loss, autosomal recessive 12.6
49 corneal dystrophy and perceptive deafness 12.6
50 cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss 12.5

Comorbidity relations with Sensorineural Hearing Loss via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Hypertension, Essential
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Sensorineural Hearing Loss:



Diseases related to Sensorineural Hearing Loss

Symptoms & Phenotypes for Sensorineural Hearing Loss

UMLS symptoms related to Sensorineural Hearing Loss:


tinnitus

MGI Mouse Phenotypes related to Sensorineural Hearing Loss:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 10 MYO6 MYO7A ATP6V1B1 OTOF COCH DLX5
2 behavior/neurological MP:0005386 9.96 MYO6 MYO7A ATP6V1B1 OTOF DLX5 SLC26A4
3 nervous system MP:0003631 9.77 MYO6 MYO7A ATP6V1B1 OTOF DLX5 GJB2
4 no phenotypic analysis MP:0003012 9.23 MYO7A OTOF SERPINB6 GJB2 GJB3 GJB6

Drugs & Therapeutics for Sensorineural Hearing Loss

Drugs for Sensorineural Hearing Loss (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 1,Phase 2 15663-27-1 84093 441203 2767
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
4 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
5 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
6 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
11 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
12
protease inhibitors Phase 4,Phase 3,Phase 2
13 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
14 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
15 Dexamethasone 21-phosphate Phase 4,Phase 2
16 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
17 BB 1101 Phase 4,Phase 3,Phase 2,Not Applicable
18 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
19
Ganciclovir Approved, Investigational Phase 3,Phase 2 82410-32-0 3454
20
Acyclovir Approved Phase 2, Phase 3 59277-89-3 2022
21
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
22
Valganciclovir Approved, Investigational Phase 3,Phase 2 175865-60-8 64147
23
Prednisone Approved, Vet_approved Phase 2, Phase 3,Phase 3 53-03-2 5865
24 Estradiol valerate Approved, Investigational, Vet_approved Phase 3 979-32-8
25
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
26
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
27
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
28
Acetylcysteine Approved, Investigational Phase 2, Phase 3,Phase 1 616-91-1 12035
29
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
30
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
31
Polyestradiol phosphate Approved Phase 3 28014-46-2
32
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
33
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
34
Iron Approved Phase 2, Phase 3 7439-89-6 23925
35
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
36
Povidone Approved Phase 3 9003-39-8
37
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
38
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
39
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
41 Analgesics Phase 3,Phase 1,Phase 2
42 calcium channel blockers Phase 3
43 Central Nervous System Depressants Phase 3
44 Ganciclovir triphosphate Phase 3,Phase 2
45 Tocolytic Agents Phase 3
46 Anesthetics Phase 3,Phase 1,Phase 2
47 Anti-Arrhythmia Agents Phase 3
48 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2,Not Applicable
49 Anticonvulsants Phase 3
50 Anti-Infective Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 122)
# Name Status NCT ID Phase Drugs
1 Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone Treatment Completed NCT01372904 Phase 4 Dexamethasone Phosphate
2 Diaphragmatic Movement Before and After Stellate Ganglion Block : A Ultrasonographic Study Completed NCT01054378 Phase 4
3 Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss Unknown status NCT00416143 Phase 2, Phase 3 prednisone - oral corticosteroid 1mg/kg/D for 1 week
4 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
5 Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
6 Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Unknown status NCT01216800 Phase 3
7 Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy Unknown status NCT01646619 Phase 3 Magnesium Sulphate;Placebo
8 AM-111 in the Treatment of Acute Inner Ear Hearing Loss Completed NCT02561091 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
9 Safety and Efficacy of Intratympanic Application of Dexamethasone Via Catheter in Patients With Sudden Hearing Loss Completed NCT00335920 Phase 3 Dexamethasone-dihydrogenphosphate (4mg/ml)
10 Evaluation of a Binaural Spatialization Method for Hearing Aids Completed NCT02693704 Phase 2, Phase 3
11 Sudden Deafness Treatment Trial Completed NCT00097448 Phase 3 prednisone;methylprednisolone sodium succinate
12 Somatropin Treatment to Final Height in Turner Syndrome Completed NCT00191113 Phase 3 Somatropin;Ethinyl estradiol;Medroxyprogesterone acetate
13 Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery Recruiting NCT03374514 Phase 3 Dexamethasone;Sterile isotonic saline solution
14 Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance Recruiting NCT02606266 Phase 2, Phase 3 Valganciclovir
15 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Active, not recruiting NCT01376778 Phase 3 CMV hyperimmune globulin
16 Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL Not yet recruiting NCT03331627 Phase 3 STR001-IT and STR001-ER
17 Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants Not yet recruiting NCT03107871 Phase 3 Valganciclovir;Simple Syrup
18 Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy Not yet recruiting NCT02882477 Phase 2, Phase 3 Deferiprone;Acetylcysteine;Sitagliptin and Metformin
19 Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment Terminated NCT02809118 Phase 3 AM-111 0.4 mg/ml;AM-111 0.8 mg/ml
20 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial Terminated NCT01655212 Phase 3 Valganciclovir
21 Autoimmunity in Inner Ear Disease Terminated NCT00000361 Phase 3 Corticosteroids;Methotrexate
22 Effectiveness of P02 Digital Hearing Aids Unknown status NCT01902914 Phase 1, Phase 2
23 Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity Unknown status NCT01108601 Phase 1, Phase 2 Ringer's Lactate (0.03% Ciprofloxacin)
24 Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss Completed NCT00802425 Phase 2 AM-111;placebo
25 Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss Completed NCT02038972 Phase 1, Phase 2
26 A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease Completed NCT01267994 Phase 1, Phase 2 Anakinra
27 Study to Evaluate SPI-1005 in Adults With Meniere's Disease Completed NCT02603081 Phase 1, Phase 2 SPI-1005
28 Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus Completed NCT00860808 Phase 2 AM-101
29 Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease Completed NCT01133860 Phase 2 eltrombopag
30 The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease Completed NCT01950312 Phase 2 gevokizumab
31 High Dose Oral Steroids in Sudden Sensorineural Hearing Loss Recruiting NCT03255473 Phase 2 Dexamethasone;Prednisone
32 Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss Recruiting NCT01621256 Phase 1, Phase 2 Ancrod;Saline solution
33 Effectiveness of Therapy Via Telemedicine Following Cochlear Implants Recruiting NCT02497690 Phase 2
34 SPI-1005 for Prevention and Treatment of Aminoglycoside Induced Ototoxicity Enrolling by invitation NCT02819856 Phase 1, Phase 2 Placebo;SPI-1005 Ebselen 200mg Capsule x1;SPI-1005 Ebselen 200mg Capsule x2;SPI-1005 Ebselen 200mg Capsule x3
35 SPI-1005 for the Treatment of Patients With Meniere's Disease Enrolling by invitation NCT03325790 Phase 2 200mg SPI-1005 BID;400mg SPI-1005 BID
36 Asymptomatic Congenital CMV Treatment Not yet recruiting NCT03301415 Phase 2 Valganciclovir
37 Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss Suspended NCT02616172 Phase 1, Phase 2
38 Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss Terminated NCT02414152 Phase 1, Phase 2 anakinra
39 A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss Completed NCT01518920 Phase 1 PF-04958242;PF-04958242;Placebo
40 Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding Completed NCT00582946 Phase 1
41 Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Completed NCT02259595 Phase 1 HPN-07;NAC;Placebo
42 Middle-Ear Implant With MET V Transducer (Aka MET V System) Unknown status NCT01529333 Not Applicable
43 Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery Unknown status NCT02093806
44 Fludrocortisone for Sudden Hearing Loss Unknown status NCT01186185 Not Applicable Fludrocortisone
45 Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis Unknown status NCT02252601 Not Applicable
46 Cochlear Implant and Vestibular Function. Unknown status NCT02584361 Not Applicable
47 Balance Control and Maturation in Normal and Deaf Children Aged From 6 to 14 Years Old Unknown status NCT00140699
48 Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals Completed NCT00787189 Not Applicable
49 Central Auditory Processing and the Use of Hearing Aids Completed NCT01897181 Not Applicable
50 Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study Completed NCT00589511

Search NIH Clinical Center for Sensorineural Hearing Loss

Cochrane evidence based reviews: hearing loss, central

Genetic Tests for Sensorineural Hearing Loss

Genetic tests related to Sensorineural Hearing Loss:

# Genetic test Affiliating Genes
1 Sensorineural Hearing Loss 29

Anatomical Context for Sensorineural Hearing Loss

MalaCards organs/tissues related to Sensorineural Hearing Loss:

41
Bone, Testes, Brain, Endothelial, Bone Marrow, Neutrophil, Pituitary

Publications for Sensorineural Hearing Loss

Articles related to Sensorineural Hearing Loss:

(show top 50) (show all 1107)
# Title Authors Year
1
Prognostic factors regarding the hearing outcome in severe to profound sudden sensorineural hearing loss treated by tympanotomy and sealing of labyrinthine windows after ineffective systemic corticosteroid application. ( 29855690 )
2018
2
Disruptive Hearing Technologies and Mild Sensorineural Hearing Loss II: Current Research on Affordable Hearing Technologies and Direct-to-Consumer Models. ( 29915452 )
2018
3
Risk factors of sensorineural hearing loss in patients with unilateral safe chronic suppurative otitis media. ( 29331307 )
2018
4
Association of Sudden Sensorineural Hearing Loss With Risk of Cardiocerebrovascular Disease: A Study Using Data From the Korea National Health Insurance Service. ( 29270613 )
2018
5
Which Patients With Asymmetric Sensorineural Hearing Loss Should Undergo Imaging? ( 29392735 )
2018
6
Mobile Hearing Testing Applications and the Diagnosis of Sudden Sensorineural Hearing Loss: A Cautionary Tale. ( 29227445 )
2018
7
Hypertrophic Pachymeningitis of the Internal Auditory Canal: A Rare Case of Unilateral Sudden Sensorineural Hearing Loss. ( 29938521 )
2018
8
Assessment of Spontaneous Recovery Rates in Patients With Idiopathic Sudden Sensorineural Hearing Loss. ( 29931029 )
2018
9
Comparison of intratympanic dexamethasone therapy and hyperbaric oxygen therapy for the salvage treatment of refractory high-frequency sudden sensorineural hearing loss. ( 29891394 )
2018
10
Bony cochlear nerve canal stenosis in pediatric unilateral sensorineural hearing loss. ( 29447896 )
2018
11
Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic sudden sensorineural hearing loss: a randomized controlled trial. ( 29149379 )
2018
12
Utilization of diagnostic testing for pediatric sensorineural hearing loss. ( 29958610 )
2018
13
Oral and intratympanic steroid therapy for idiopathic sudden sensorineural hearing loss. ( 29721537 )
2018
14
Compensated Vestibular Dysfunction Post Cochlear Implantation in Children with Sensorineural Hearing Loss: A Prospective Study. ( 29977841 )
2018
15
The role of explorative tympanotomy in patients with sudden sensorineural hearing loss with and without perilymphatic fistula. ( 29055686 )
2018
16
Fever of unknown origin, bilateral sensorineural hearing loss with canal paresis and uveitis with iridocyclitis and episcleritis: a case of Cogan's syndrome. ( 29703835 )
2018
17
A protocol for a network meta-analysis of interventions to treat patients with sudden sensorineural hearing loss. ( 29769117 )
2018
18
Delayed Recovery in Pediatric Sudden Sensorineural Hearing Loss Predicted via Magnetic Resonance Imaging. ( 29717656 )
2018
19
Unilateral Sensorineural Hearing Loss Presenting With Bilateral Temporal Bone Lesions. ( 29342040 )
2018
20
Inpatient treatment of patients with idiopathic sudden sensorineural hearing loss: a population-based healthcare research study. ( 29330597 )
2018
21
Association of Vertigo With Hearing Outcomes in Patients With Sudden Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. ( 29931169 )
2018
22
Azithromycin and Sensorineural Hearing Loss in Adults: A Retrospective Cohort Study. ( 29965935 )
2018
23
Idiopathic Sudden Sensorineural Hearing Loss Is Not a Sentinel Event for Acute Myocardial Infarction. ( 29912831 )
2018
24
Prognostic role of haematological indices in sudden sensorineural hearing loss: Review and meta-analysis. ( 29684383 )
2018
25
Can A Sudden Sensorineural Hearing Loss Occur Due to Miliary Tuberculosis? ( 29036759 )
2018
26
Comparison of 2 and 4 Intratympanic Steroid Injections in the Treatment of Idiopathic Sudden Sensorineural Hearing Loss. ( 29411622 )
2018
27
Association of Idiopathic Sudden Sensorineural Hearing Loss With Affective Disorders. ( 29852049 )
2018
28
The Clinical Value of Vertigo as a Prognostic Indicator of Outcome in Sudden Sensorineural Hearing Loss. ( 29931206 )
2018
29
Mobile phone usage does not affect sudden sensorineural hearing loss. ( 29179790 )
2018
30
Association of Metabolic Syndrome With Sudden Sensorineural Hearing Loss. ( 29450496 )
2018
31
Benefits from, Satisfaction with, and Self-Efficacy for Advanced Digital Hearing Aids in Users with Mild Sensorineural Hearing Loss. ( 29915453 )
2018
32
Coexistence of IL-6 -572C/G and ICAM-1 K469E Polymorphisms among Patients with Sudden Sensorineural Hearing Loss. ( 29695657 )
2018
33
The Characteristic and Short-Term Prognosis of Tinnitus Associated with Sudden Sensorineural Hearing Loss. ( 29861716 )
2018
34
Spastic paraparesis and sensorineural hearing loss: keep brucellosis in mind. ( 29406895 )
2018
35
TMTC2 variant associated with sensorineural hearing loss and auditory neuropathy spectrum disorder in a family dyad. ( 29671961 )
2018
36
Modified Siegel's criteria for sudden sensorineural hearing loss: Reporting recovery outcomes with matched pretreatment hearing grades. ( 29929833 )
2018
37
Sensorineural Hearing Loss and Congenital Cytomegalovirus Infection. ( 29441223 )
2018
38
Contralateral sensorineural hearing loss after vestibular schwannoma surgery. ( 29929725 )
2018
39
Low-Frequency Sensorineural Hearing Loss in Familial Hemophagocytic Lymphohistiocytosis Type 5. ( 29776323 )
2018
40
Effect of Antioxidant Vitamins as Adjuvant Therapy for Sudden Sensorineural Hearing Loss: Systematic Review Study. ( 29929192 )
2018
41
Prevalence of otitis media and risk-factors for sensorineural hearing loss among infants attending Child Welfare Clinics in the Solomon Islands. ( 29958609 )
2018
42
Sudden Sensorineural Hearing Loss in the Department of Defense. ( 29631507 )
2018
43
Hearing Aids as a Treatment for Tinnitus Patients with Slight to Mild Sensorineural Hearing Loss. ( 29915450 )
2018
44
Disruptive Hearing Technologies and Mild Sensorineural Hearing Loss I: Accessibility and Affordability Issues. ( 29915451 )
2018
45
B3GALNT2-Related Dystroglycanopathy: Expansion of the Phenotype with Novel Mutation Associated with Muscle-Eye-Brain Disease, Walker-Warburg Syndrome, Epileptic Encephalopathy-West Syndrome, and Sensorineural Hearing Loss. ( 29791932 )
2018
46
Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. ( 29470486 )
2018
47
Acupuncture as an early treatment for idiopathic sudden sensorineural hearing loss (ISSNHL) patients with flat or high-frequency drop audiograms: study protocol for a randomized controlled trial. ( 29973265 )
2018
48
Is nucleate cell count and neutrophil to lymphocyte ratio related to patients with audiographically distinct sudden sensorineural hearing loss? ( 29768325 )
2018
49
Sensorineural hearing loss in children with sickle cell anemia and its association with endothelial dysfunction. ( 29806800 )
2018
50
Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2. ( 29416648 )
2018

Variations for Sensorineural Hearing Loss

ClinVar genetic disease variations for Sensorineural Hearing Loss:

6
(show all 20)
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-TL1 m.3243A> G single nucleotide variant Pathogenic rs199474657 GRCh37 Chromosome MT, 3243: 3243
2 MT-TL1 m.3243A> G single nucleotide variant Pathogenic rs199474657 GRCh38 Chromosome MT, 3243: 3243
3 46;XY;t(8;9)(q13;p22)dn Translocation Pathogenic
4 46;XY;t(5;7)(q14.3;q21.3)dn Translocation Likely pathogenic
5 46;XX;t(1;13)(q11.2;p11.2)dn Translocation Uncertain significance
6 46;XY;t(6;11)(p12.3;p14.2)dn Translocation Pathogenic
7 MT-CYB NC_012920.1: m.15127C> T single nucleotide variant Uncertain significance rs1057516074 GRCh37 Chromosome MT, 15127: 15127
8 MT-CYB NC_012920.1: m.15127C> T single nucleotide variant Uncertain significance rs1057516074 GRCh38 Chromosome MT, 15127: 15127
9 COL11A2 NM_080680.2(COL11A2): c.4430G> T (p.Gly1477Val) single nucleotide variant Likely pathogenic rs745434198 GRCh37 Chromosome 6, 33133760: 33133760
10 COL11A2 NM_080680.2(COL11A2): c.4430G> T (p.Gly1477Val) single nucleotide variant Likely pathogenic rs745434198 GRCh38 Chromosome 6, 33165983: 33165983
11 MYH14 NM_001145809.1(MYH14): c.1945+6G> A single nucleotide variant Uncertain significance rs1057518869 GRCh37 Chromosome 19, 50756016: 50756016
12 MYH14 NM_001145809.1(MYH14): c.1945+6G> A single nucleotide variant Uncertain significance rs1057518869 GRCh38 Chromosome 19, 50252759: 50252759
13 AIFM1 NM_004208.3(AIFM1): c.1019T> C (p.Met340Thr) single nucleotide variant Likely pathogenic rs1057518895 GRCh38 Chromosome X, 130137134: 130137134
14 AIFM1 NM_004208.3(AIFM1): c.1019T> C (p.Met340Thr) single nucleotide variant Likely pathogenic rs1057518895 GRCh37 Chromosome X, 129271109: 129271109
15 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh37 Chromosome 1, 151378740: 151378740
16 POGZ NM_015100.3(POGZ): c.2771delC (p.Pro924Argfs) deletion Pathogenic GRCh38 Chromosome 1, 151406264: 151406264
17 ESPN NM_031475.2(ESPN): c.2150A> G (p.Asn717Ser) single nucleotide variant Uncertain significance rs921702586 GRCh37 Chromosome 1, 6511981: 6511981
18 ESPN NM_031475.2(ESPN): c.2150A> G (p.Asn717Ser) single nucleotide variant Uncertain significance rs921702586 GRCh38 Chromosome 1, 6451921: 6451921
19 GSDME NM_001127453.1(GSDME): c.456T> G (p.Asn152Lys) single nucleotide variant Uncertain significance rs148449230 GRCh38 Chromosome 7, 24719167: 24719167
20 GSDME NM_001127453.1(GSDME): c.456T> G (p.Asn152Lys) single nucleotide variant Uncertain significance rs148449230 GRCh37 Chromosome 7, 24758786: 24758786

Copy number variations for Sensorineural Hearing Loss from CNVD:

7 (show all 13)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 115500 17 58121080 60118579 Deletion Sensorineural hearing loss
2 115503 17 58121080 60118579 Deletion APPBP2 sensorineural hearing loss
3 115507 17 58121080 60118579 Deletion BCAS3 sensorineural hearing loss
4 115511 17 58121080 60118579 Deletion BRIP1 sensorineural hearing loss
5 115515 17 58121080 60118579 Deletion CA4 sensorineural hearing loss
6 115519 17 58121080 60118579 Deletion INTS2 sensorineural hearing loss
7 115523 17 58121080 60118579 Deletion MED13 sensorineural hearing loss
8 115527 17 58121080 60118579 Deletion NACA2 sensorineural hearing loss
9 115531 17 58121080 60118579 Deletion PPM1D sensorineural hearing loss
10 115535 17 58121080 60118579 Deletion TBX2 sensorineural hearing loss
11 115539 17 58121080 60118579 Deletion TBX4 sensorineural hearing loss
12 115543 17 58121080 60118579 Deletion USP32 sensorineural hearing loss
13 115552 17 58172730 60315273 Deletion Sensorineural hearing loss

Expression for Sensorineural Hearing Loss

Search GEO for disease gene expression data for Sensorineural Hearing Loss.

Pathways for Sensorineural Hearing Loss

Pathways related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.92 GJB2 GJB3 GJB6 MYO6

GO Terms for Sensorineural Hearing Loss

Cellular components related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 9.55 ATP6V1B1 GJB6 MYO7A SLC26A4 USH2A
2 microvillus GO:0005902 9.5 ATP6V1B1 MYO6 MYO7A
3 myosin complex GO:0016459 9.43 MYH9 MYO6 MYO7A
4 gap junction GO:0005921 9.13 GJB2 GJB3 GJB6
5 connexin complex GO:0005922 8.8 GJB2 GJB3 GJB6

Biological processes related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule-based movement GO:0007018 9.63 MYH9 MYO6 MYO7A
2 inner ear development GO:0048839 9.5 GJB2 GJB6 MYO7A
3 calcium ion homeostasis GO:0055074 9.48 ATP6V1B1 WFS1
4 sensory perception of sound GO:0007605 9.44 ATP6V1B1 COCH GJB2 GJB6 KCNQ4 MYO6
5 regulation of pH GO:0006885 9.43 ATP6V1B1 SLC26A4
6 cell communication GO:0007154 9.43 GJB2 GJB3 GJB6
7 sensory perception of light stimulus GO:0050953 9.4 MYO7A USH2A
8 inner ear receptor cell differentiation GO:0060113 9.37 MYO7A USH2A
9 actin filament-based movement GO:0030048 9.33 MYH9 MYO6 MYO7A
10 inner ear morphogenesis GO:0042472 9.26 ATP6V1B1 DLX5 KCNQ4 MYO7A

Molecular functions related to Sensorineural Hearing Loss according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule motor activity GO:0003777 9.58 MYH9 MYO6 MYO7A
2 motor activity GO:0003774 9.5 MYH9 MYO6 MYO7A
3 microfilament motor activity GO:0000146 9.37 MYH9 MYO7A
4 gap junction channel activity GO:0005243 9.26 GJB2 GJB3
5 actin-dependent ATPase activity GO:0030898 9.16 MYH9 MYO7A
6 ADP binding GO:0043531 9.13 MYH9 MYO6 MYO7A
7 calmodulin binding GO:0005516 9.02 KCNQ4 MYH9 MYO6 MYO7A WFS1

Sources for Sensorineural Hearing Loss

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....